Small molecule · developed by Lakefront Biotherapeutics NV
GLPG3970 is an investigational oral drug studied in healthy volunteers and in patients with psoriasis, systemic lupus erythematosus and primary Sjögren syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04700280 | Phase 2 | Primary Sjögren Syndrome | Terminated | LKFT |
| NCT04907149 | Phase 1 | Healthy | Completed | LKFT |
| NCT04700267 | Phase 1 | Systemic Lupus Erythematosus | Terminated | LKFT |
| NCT04106297 | Phase 1 | Healthy | Completed | LKFT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HealthyPrimary Sjögren SyndromePsoriasisSystemic Lupus Erythematosus
Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.
See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LKFT catalysts and pipeline →